As a University and a Department we have a huge responsibility to make sure that our research gets translated into real benefits for society
- Daan Frenkel
The University of Cambridge has been awarded more than £17 million in funding to support research into the molecular origins of human disease, particularly neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, and to accelerate the development new diagnostic and therapeutic methods of treating them.
The funding has been awarded from the fourth round of the UK Research Partnership Investment Fund (UKRPIF). Seven university research projects from across the UK will receive over £100 million of investment in 2016-17, to drive innovation and economic growth.
The projects will promote the development of world-leading research in a range of subject areas, from semiconductors to neuroscience, and have collectively attracted £350 million of private investment, in addition to the £100 million of UKRPIF funding.
The Cambridge funding will be used to support the construction of a new £22 million Chemistry of Health building, expected to be completed by March 2017, which will provide world-class facilities for chemistry-based fundamental research in neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases.
The new building will promote the translation of fundamental research into clinical and commercial applications by providing the infrastructure required for new academic-industrial partnerships, which will have both immediate and long-term benefits for human health and the UK economy.
Read the full story
Image:Brain showing hallmarks of Alzheimer's disease (cropped)
Credit: ZEISS Microscopy
Reproduced courtesy of the University of Cambridge
__________________________________________